目的 探究鹤蟾片联合DP方案治疗非小细胞肺癌的临床疗效。方法 选取2015年5月-2017年2月西安市胸科医院收治的非小细胞肺癌患者80例为研究对象，按随机数字表法分为对照组（41例）和治疗组（39例）。对照组第1天静脉滴注多西他赛注射剂，60 mg/m²；第1~3天静脉滴注注射用顺铂，25 mg/m²，21 d为1个周期，治疗2个周期。治疗组在对照组基础上口服鹤蟾片，6片/次，3次/d，直至放化疗结束。观察两组的临床疗效，比较两组的肿瘤标志物、生活质量、T细胞亚群、生存情况、毒副反应。结果 治疗后，对照组和治疗组的客观有效率分别为39.02%、61.54%，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清细胞角蛋白21片段（Cyfra21-1）、癌胚抗原（CEA）、糖类抗原125（CA125）水平均明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组肿瘤标志物水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组生理状态（PWB）评分、肺癌附加的关注（LCS）评分、肺癌生存质量评价量表（FACT-L）总分和Karnofsky（KPS）评分明显升高，治疗组PWB评分、功能状态（FWB）评分、情感状态（EWB）评分、LCS评分、FACT-L总分和KPS评分明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些评分明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，对照组CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明显下降，CD8⁺水平明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组T细胞亚群水平明显优于对照组，两组比较差异具有统计学意义（P<0.05）。随访后，对照组和治疗组中位无进展生存期分别为5.3、7.5个月，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组白细胞计数减少、肾功能损害、肝功能损害、腹泻的发生率明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 鹤蟾片联合DP方案治疗非小细胞肺癌具有较好的临床疗效，能降低肿瘤标志物水平，提高患者免疫力，减轻毒副反应，改善生活质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Hechan Tablets combined with DP chemotherapy in treatment of non-small cell lung cancer. Methods Patients (80 cases) with non-small cell lung cancer in Xi'an Chest Hospital from May 2015 to February 2012 were randomly divided into the control group (41 cases) and the treatment group (39 cases). Patients in the control group were iv administered with Docetaxel Injection at the first day, 60 mg/m², and at the first to third day, patients in the control group were also iv administered with Cisplatin for injection, 25 mg/m², treated for 2 cycles (21 d for one cycle). Patients in the treatment group were po administered with Hechan Tablets on the basis of the control group, 6 tablets/time, three times daily, treated for the end of radiotherapy and chemotherapy. After treatment, the clinical efficacies were evaluated, and tumor markers, quality of life, T cell subsets, survival situation, and side effects in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 39.02% and 61.54%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of Cyfra21-1, CEA, and CA125 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the tumor markers in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, PWB score, LCS score, FACT-L score, and KPS score in the control group were significantly increased, and PWB score, FWB score, EWB score, LCS score, FACT-L score, and KPS score in the treatment group were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly decreased, but the levels of CD8⁺ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the T cell subsets in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After followed up, the PFS in the control and treatment groups were 5.3 months and 7.5 months, respectively, and there was difference between two groups (P<0.05). After treatment, the incidence rates of white blood cell count decreased, renal damage, liver damage, and diarrhea in the treatment group were significantly lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Hechan Tablets combined with DP chemotherapy has clinical curative effect in treatment of non-small cell lung cancer, can decrease the level of tumor marker, improve the immunity of patients, reduce the side effects and improve the quality of life, which has a certain clinical application value.